Fda clears ind for inkt cells to treat covid-19 patients

Fda clears ind for inkt cells to treat covid-19 patients.agenus - agentus allogeneic inkts have potential to clear sars-cov-2 virus, mitigate harmful inflammation.agenus - clinical trial for treatment of patients with covid-19 expected to commence shortly.agenus - contemplating several options regarding agentus therapeutics subsidiary.agenus - options include potential of spinning out agentus.agenus - options include issuing portion of holdings in agentus to agenus shareholders in form of stock dividend.agenus - expects that decision for agentus will be made by end of this year.
AGEN Ratings Summary
AGEN Quant Ranking